The short answer: nobody has published a controlled trial of GHK-Cu alone on thinning scalp hair. The only randomized human trial of GHK-Cu on hair put it on one eyebrow of 18 young adults for 12 weeks. Everything else is hair follicles in a dish, mice and rats, or scalp treatments where copper peptide was one ingredient among many.
Minoxidil and finasteride, by contrast, have FDA labels and trials in hundreds to thousands of people. So "GHK-Cu vs minoxidil" isn't a contest between two tested options yet.
Status as of October 30, 2026: GHK-Cu is not FDA-approved for hair loss or any other use. Copper peptide hair serums are sold as cosmetics, and a cosmetic can't legally claim to restore hair growth. This post describes what studies and drug labels measured. It isn't medical advice. Sudden or patchy hair loss is a reason to see a doctor before buying anything.
Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.
Where I get mine: the vendors I use, and how I vetted them.
Does GHK-Cu help with hair growth?
Not shown in people's scalps. Here's every kind of evidence that exists, from weakest to strongest.
Study type | What was tested | Who, how many | How long | What it found |
|---|---|---|---|---|
Hair follicles in a dish (2007) | AHK-Cu, a different copper peptide | Human follicles and cells, no people | Lab only | Follicles grew longer, cells multiplied |
Animals (1991, 1993, 2023) | Copper peptides on mice and rats | Animals | Varies | Bigger follicles, more growth |
Eyebrow trial (2026) | 2% GHK-Cu serum vs placebo, one brow each | 18 healthy adults, 18 to 40 | 12 weeks | More brow hairs and thicker hairs on the treated side |
Scalp trial (2016) | Copper-free GHK bonded to another compound, vs placebo | 45 men with pattern hair loss | 6 months | Higher hair counts, no change in thickness |
Scalp injection and tattoo studies (2018, 2025) | Mixes where copper peptide was one of several actives | 7 to 1,000 people, no placebo group | Months | Improvements, but nothing shows what the copper peptide did |
Sources: Pyo, 2007, Uno, 1993, Liu, 2023, Bo, 2026, Lee, 2016, Kapoor, 2018, Kuceki, 2025.
A PubMed search on October 30 for copper peptides and hair returned 19 records, none a controlled trial of GHK-Cu alone on the scalp. ClinicalTrials.gov lists no GHK-Cu hair trial.
What has GHK-Cu actually been tested on for hair?
Mostly cells and rodents. That's where ideas start, not where they're proven.
The follicle study everyone cites isn't GHK-Cu. The 2007 paper behind most "copper peptides grow hair" claims tested AHK-Cu, a cousin with one different amino acid. It made human hair follicles in a dish grow longer and made the cells at their base multiply (Arch Pharm Res, 2007).
The animal studies are few. A 1991 mouse report came from researchers at ProCyte, a copper peptide company, with GHK-Cu's discoverer, Loren Pickart, as a coauthor. PubMed lists no abstract for it, just the title (Ann N Y Acad Sci, 1991). A 2023 mouse study found a special emulsion pushed about three times more copper peptide into skin (Bioact Mater, 2023).
The reviews lean on one group. A 2026 systematic review found that about 35% of the GHK-Cu research it covered had Pickart or his colleague Anna Margolina as an author, and said that concentration "limits the independence of the evidence base" (Arch Intern Med Res, 2026).
Is there a human study of GHK-Cu for hair loss?
One small trial on eyebrows, and one scalp trial that used GHK without the copper. Neither was in older adults with thinning hair.
The eyebrow trial. Researchers in Thailand gave 18 healthy adults aged 18 to 40 a 2% GHK-Cu serum for one eyebrow and a placebo serum for the other, twice a day for 12 weeks. Hair count and hair diameter improved on the treated side, and no serious side effects or allergic reactions were reported (Bo, 2026). The abstract gives no hair counts. An independent review called it "the strongest recent controlled cosmetic signal," but "a small single-center study" with test material nobody characterized chemically (Pharmaceutics, 2026). It isn't in PubMed.
The scalp trial. In Korea, 45 men aged 25 to 60 with male pattern hair loss sprayed one of two strengths of a compound or a placebo on their scalp daily for 6 months. Hair counts rose by 52.6 and 71.5 in the two treatment groups vs 9.6 on placebo. Hair length and thickness didn't differ between groups (Ann Dermatol, 2016). The catch: the compound was GHK bonded to 5-aminolevulinic acid, and its chemical formula contains no copper. It's the best scalp data in the GHK family, and it isn't GHK-Cu.
Pickart's 2018 review lists "increase hair growth and thickness" among things GHK-Cu is "established" to do (Int J Mol Sci, 2018). The human hair evidence above is what that rests on.
GHK-Cu vs minoxidil: which works better for hair?
Nobody has tested them head to head in people. Minoxidil has the trials. GHK-Cu doesn't.
The "as good as minoxidil" line has roots in a 1993 rat study. Its abstract says a copper-binding peptide coded PC1031 enlarged hair follicles on hairless rats, and "the effect was similar to that of topical minoxidil" (J Invest Dermatol, 1993). That's the oldest version of the comparison I could find in PubMed. It's rats, and the abstract doesn't say PC1031 is GHK-Cu.
Minoxidil (topical) | Finasteride (pill) | GHK-Cu | |
|---|---|---|---|
FDA status | Over the counter, to regrow hair on top of the scalp | Prescription, male pattern hair loss in men only | Not approved for hair or anything else |
Key controlled hair trials | 393 men and 381 women, 48 weeks | 1,879 men, 12 months | 18 adults, eyebrows, 12 weeks |
Ages in those trials | 18 to 49 | 18 to 41 | 18 to 40 |
Tested in women | Yes, and labeled for women | Failed in 137 postmenopausal women | No scalp data in women |
When the label says to judge it | At least 4 months (men), 6 months (some women) | Three months or more | No label |
Sources: Olsen, JAAD, 2002, Lucky, JAAD, 2004, Propecia label, women's minoxidil label, men's minoxidil label, Bo, 2026.
Minoxidil's own label (Rogaine) has limits too. The men's version is "not intended for frontal baldness or receding hairline," and it says to stop and ask a doctor if you get chest pain, a rapid heartbeat or dizziness (DailyMed). In the trials, the 5% solution caused more itching and irritation than the 2% (Olsen, 2002).
What about finasteride?
It's the best-tested option for men and the worst-tested for everyone else. Three placebo-controlled trials in 1,879 men found a 107-hair difference from placebo at 12 months, counted in a one-inch circle (Propecia label).
The label's limits:
Sexual side effects were reported in 3.8% of men on the drug vs 2.1% on placebo in year one.
Reports after approval include "depression, suicidal ideation and behavior."
Stopping it "leads to reversal of effect within 12 months."
It's contraindicated in women who are or may become pregnant.
GHK-Cu has no side-effect record at this scale because it has no trial at this scale. No data isn't proof of safety.
Can you use GHK-Cu and minoxidil together?
It hasn't been tested as a pair. The only human reports that combine them are uncontrolled procedures that mix in other drugs, so they can't tell you what the copper added.
Scalp tattooing, 7 men. A tattoo machine delivered minoxidil, dutasteride (a finasteride relative) and copper peptides into the scalp over 5 monthly sessions. Scalp coverage scores improved. It was a look back at clinic records with no control group, and the men kept using topical minoxidil throughout (JAAD Int, 2025).
A clinic series of 18,918 men. Finasteride, minoxidil and monthly injections of a 14-ingredient mix that included copper tripeptide (J Clin Aesthet Dermatol, 2018). Any gain there has two approved drugs in it.
GHK-Cu injection for hair: what's been tested?
No published study has injected GHK-Cu alone into a human scalp. The injection data is in mice, or in people getting a cocktail.
In an open-label study of 1,000 patients with no placebo group, scalp injections of growth factors, thymosin beta-4 and copper tripeptide-1 every 3 weeks reduced hair fall on a pull test in 83% (J Cosmet Laser Ther, 2018). Six actives, no comparison group.
The same clinic's mouse study of a similar mix found hair kept within about a quarter centimeter of each injection site (Plast Reconstr Surg Glob Open, 2020).
On injectable GHK-Cu in general, FDA's compounding safety page says it "may pose risk for immunogenicity" from aggregation and impurities, and that "there are limited data in humans" (FDA, Apr 2026). The August Pharmaceutics review calls loose copper that isn't bound to the peptide "the single most consequential attribute in this product class" (Pharmaceutics, 2026). It's the same issue behind why GHK-Cu burns. For the skin side of the cream-or-needle question, see GHK-Cu cream vs injection.
Thinning hair after 50, and in women
This is where the evidence is thinnest for everything, not just copper peptide.
The big trials stopped before 50. The minoxidil trials enrolled ages 18 to 49, and finasteride's ran 18 to 41. Finasteride's label says its efficacy studies "did not include subjects aged 65 and over."
Finasteride failed in older women. In 137 postmenopausal women with pattern hair loss, 12 months on the drug produced no improvement in hair counts or ratings vs placebo (Propecia label).
Minoxidil is the one labeled for women. In a 48-week trial of 381 women aged 18 to 49, 5% minoxidil beat placebo on all three main measures (JAAD, 2004). The women's label says some women need at least 6 months to see results.
GHK-Cu has no scalp data in women at all. The eyebrow trial didn't report sex and stopped at age 40. The scalp trial was all men.
One more thing the minoxidil label gets right: don't use it if your hair loss is "sudden and/or patchy," came after childbirth, or you "do not know the reason" (DailyMed). Those are questions for a doctor first, and one more reason for blood work before peptides. If the shedding started on a GLP-1, the tirzepatide label ties hair loss to weight reduction, reported in 7.1% of women vs 1.3% on placebo (Zepbound label). More on that in is reta safe.
GHK-Cu hair before and after: what did the studies measure?
Counts in small zones, photos and self-ratings, over weeks to months. No study tracked whether gains held after stopping.
The eyebrow trial counted brow hairs and measured diameter.
The Korean scalp trial counted hairs with a magnifying scalp camera and asked men to rate their satisfaction.
The tattoo study had four dermatologists rate scalp photos, and admitted it lacked "objective scoring measures."
A 2024 dandruff study with a copper peptide serum ran 15 days, had no control group, tested five actives at once, and had an author employed by the product's maker (Cureus, 2024).
So a before-and-after photo online is marketing, not a study result.
Is GHK-Cu for hair legal?
As a cosmetic, yes. FDA says cosmetics don't need approval, but a product that claims to "restore hair growth" is a drug (FDA). So a cosmetic hair serum can talk about how hair looks. It can't legally promise regrowth.
Injectable GHK-Cu isn't approved for anything. FDA plans to take GHK-Cu to its compounding advisory committee before the end of February 2027, with no date set as of October 30 (FDA). Its status is tracked on the compounding status tracker.
So, does GHK-Cu work for hair?
Nobody knows yet. There's a plausible lab story, some animal work and one 18-person eyebrow trial. There's no controlled trial on thinning scalp hair, none in women, none past age 60, none against minoxidil and none injecting it alone.
Minoxidil and finasteride have documented effects and documented limits. GHK-Cu has neither yet. If you try a copper peptide serum anyway, treat it as an untested cosmetic. Even the approved drugs' labels talk in months, not weeks.
If you've used a copper peptide on your scalp, reply and tell me: alone or with minoxidil, for how long, and whether you saw anything you'd call a change. There's no trial on this. You're the closest thing to one.